Patient-Friendly Explanation
Semaglutide and tirzepatide are both once-weekly injections that reduce appetite and help with significant weight loss. Tirzepatide targets two appetite hormones while semaglutide targets one, and studies show tirzepatide produces slightly larger average weight loss. The best choice depends on your medical history, side effects, and response.
Clinical Definition
Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP receptor agonist. In the head-to-head SURMOUNT-5 trial, tirzepatide 15 mg achieved a mean weight loss of approximately 20.2% versus 13.7% with semaglutide 2.4 mg over 72 weeks. Both improve cardiometabolic risk factors; gastrointestinal side effects are common with both, and dose titration under medical monitoring is required.
Why It Matters
Choosing between these medications is a clinical decision that should be made with a doctor, not a forum post. NuLifeCare’s doctors assess your medical history and goals to recommend the right medication and monitor your progress safely.